Dermatouch Hydrating Clear Moisutrizer Spf 25

Avobenzone, Homosalate, Octisalate


Spa De Soleil
Human Otc Drug
NDC 68062-8309
Dermatouch Hydrating Clear Moisutrizer Spf 25 also known as Avobenzone, Homosalate, Octisalate is a human otc drug labeled by 'Spa De Soleil'. National Drug Code (NDC) number for Dermatouch Hydrating Clear Moisutrizer Spf 25 is 68062-8309. This drug is available in dosage form of Lotion. The names of the active, medicinal ingredients in Dermatouch Hydrating Clear Moisutrizer Spf 25 drug includes Avobenzone - 1.5 mg/50mL Homosalate - 7.5 mg/50mL Octisalate - 2.5 mg/50mL . The currest status of Dermatouch Hydrating Clear Moisutrizer Spf 25 drug is Active.

Drug Information:

Drug NDC: 68062-8309
The labeler code and product code segments of the National Drug Code number, separated by a hyphen. Asterisks are no longer used or included within the product code segment to indicate certain configurations of the NDC.
Proprietary Name: Dermatouch Hydrating Clear Moisutrizer Spf 25
Also known as the trade name. It is the name of the product chosen by the labeler.
Product Type: Human Otc Drug
Indicates the type of product, such as Human Prescription Drug or Human OTC Drug. This data element corresponds to the “Document Type” of the SPL submission for the listing.
Non Proprietary Name: Avobenzone, Homosalate, Octisalate
Also known as the generic name, this is usually the active ingredient(s) of the product.
Labeler Name: Spa De Soleil
Name of Company corresponding to the labeler code segment of the ProductNDC.
Dosage Form: Lotion
The translation of the DosageForm Code submitted by the firm. There is no standard, but values may include terms like `tablet` or `solution for injection`.The complete list of codes and translations can be found www.fda.gov/edrls under Structured Product Labeling Resources.
Status: Active
FDA does not review and approve unfinished products. Therefore, all products in this file are considered unapproved.
Substance Name:AVOBENZONE - 1.5 mg/50mL
HOMOSALATE - 7.5 mg/50mL
OCTISALATE - 2.5 mg/50mL
This is the active ingredient list. Each ingredient name is the preferred term of the UNII code submitted.
Route Details:TOPICAL
The translation of the Route Code submitted by the firm, indicating route of administration. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources.

Marketing Information:

An openfda section: An annotation with additional product identifiers, such as NUII and UPC, of the drug product, if available.
Marketing Category: OTC MONOGRAPH FINAL
Product types are broken down into several potential Marketing Categories, such as New Drug Application (NDA), Abbreviated New Drug Application (ANDA), BLA, OTC Monograph, or Unapproved Drug. One and only one Marketing Category may be chosen for a product, not all marketing categories are available to all product types. Currently, only final marketed product categories are included. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources.
Marketing Start Date: 18 Jan, 2022
This is the date that the labeler indicates was the start of its marketing of the drug product.
Marketing End Date: 22 Dec, 2025
This is the date the product will no longer be available on the market. If a product is no longer being manufactured, in most cases, the FDA recommends firms use the expiration date of the last lot produced as the EndMarketingDate, to reflect the potential for drug product to remain available after manufacturing has ceased. Products that are the subject of ongoing manufacturing will not ordinarily have any EndMarketingDate. Products with a value in the EndMarketingDate will be removed from the NDC Directory when the EndMarketingDate is reached.
Application Number: part352
This corresponds to the NDA, ANDA, or BLA number reported by the labeler for products which have the corresponding Marketing Category designated. If the designated Marketing Category is OTC Monograph Final or OTC Monograph Not Final, then the Application number will be the CFR citation corresponding to the appropriate Monograph (e.g. “part 341”). For unapproved drugs, this field will be null.
Listing Expiration Date: 31 Dec, 2023
This is the date when the listing record will expire if not updated or certified by the firm.

OpenFDA Information:

An openfda section: An annotation with additional product identifiers, such as NUII and UPC, of the drug product, if available.
Manufacturer Name:Spa de Soleil
Name of manufacturer or company that makes this drug product, corresponding to the labeler code segment of the NDC.
Original Packager:Yes
Whether or not the drug has been repackaged for distribution.
UNII:G63QQF2NOX
V06SV4M95S
4X49Y0596W
Unique Ingredient Identifier, which is a non-proprietary, free, unique, unambiguous, non-semantic, alphanumeric identifier based on a substance’s molecular structure and/or descriptive information.

Packaging Information:

Package NDCDescriptionMarketing Start DateMarketing End DateSample Available
68062-8309-150 mL in 1 BOTTLE, PUMP (68062-8309-1)18 Jan, 2022N/ANo
Package NDC number, known as the NDC, identifies the labeler, product, and trade package size. The first segment, the labeler code, is assigned by the FDA. Description tells the size and type of packaging in sentence form. Multilevel packages will have the descriptions concatenated together.

Purpose:

Purpose sunscreen

Product Elements:

Dermatouch hydrating clear moisutrizer spf 25 avobenzone, homosalate, octisalate lavandula angustifolia flower cetearyl ethylhexanoate octisalate octisalate matricaria chamomilla leaf glycerin water avobenzone avobenzone homosalate homosalate

Indications and Usage:

Uses: . helps prevent sunburn. . higher spf gives more sunburn protection. . if used as directed with other sun protection measures (see directions), decreases the risk of skin cancer and early skin aging caused by the sun.

Warnings:

Warnings warnings: . for external use only. . do not use on damaged or broken skin. . when using this product keep out of eyes. rinse with water to remove. . stop use and ask a doctor if rash or irritation occurs or lasts. . if swallowed, seek medical help or contact a poison control center right away. . keep out of reach of children. . jar is glass and may shatter if dropped.

Dosage and Administration:

Directions directions: apply generously and evenly thirty minutes before sun exposure. reapply at least every two hours. use a water-resistant sunscreen if swimming or sweating. children under six months of age: consult a doctor.

Package Label Principal Display Panel:

Principal display panel dermatouchspf25fda.jpg


Comments/ Reviews:

* Data of this site is collected from www.fda.gov. This page is for informational purposes only. Always consult your physician with any questions you may have regarding a medical condition.